New pill-and-immunotherapy combo tested for advanced lung cancer
NCT ID NCT05860296
First seen Jan 11, 2026 · Last updated Apr 28, 2026 · Updated 18 times
Summary
This study tested a new pill (SLC-391) combined with an immunotherapy drug (pembrolizumab) in people with advanced non-small cell lung cancer. The goal was to see if the combination is safe and can slow tumor growth. The study was stopped early, but it aimed to find the best dose and measure how well the treatment controls the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Community Health Network
Indianapolis, Indiana, 46250, United States
-
Cross Cancer Institute
Edmonton, Alberta, Canada
-
Horizon Verdi Oncology
Lafayette, Indiana, 47905, United States
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
Juravinski Cancer Centre
Hamilton, Ontario, Canada
-
Karmanos Cancer Center
Detroit, Michigan, 48201, United States
-
London Regional Cancer Centre
London, Ontario, Canada
-
McGill University Health Centre
Montreal, Quebec, H4A 3J1, Canada
-
Nebraska Cancer Specialists
Omaha, Nebraska, 68130, United States
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Conditions
Explore the condition pages connected to this study.